Sayad Pierre Sargis's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed Aug 31, 2026
- Accession no.
- 0002043395-26-000012
- Filed
- Aug 31, 2026, 8:15 PM ET
- Trade date
- Aug 31, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $146.2K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sayad Pierre SargisCIK 0002043395 | Officer (Chief Medical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 31, 2026 | Common Shares | AGrant or awardAcquired | +168 | $0.00 | $0 | 21,519 | Direct | |
| Aug 31, 2026 | Common Shares | SSaleDisposed | −12,000 | $12.18 | −$146,160 | 9,519 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.